Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib plus Cetuximab with or without Chemotherapy in BRAF V600E-Mutant Colorectal Cancer
NCT04607421Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Dec 2020
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial of encorafenib in colorectal cancer (CRC) (7 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicity at 28 days, Progression Free Survival up to 37.25 months and 1 more. Started Dec 2020; status: active, not recruiting.
02
Drugs
encorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04607421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04607421.